Provident Financial Services Inc. (PFS)
Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act
Inhibrx is transitioning from a platform to a clinical-stage biotech, with ozekibart and INBRX-106 as key value drivers. Ozekibart's BLA for chondrosarcoma is under FDA review with an April 14, 2027 PDUFA date, supported by strong PFS and disease control data. INBRX-106 shows promising early efficacy as a PD-1 enhancer in HNSCC, with pivotal PFS data expected in Q4 2026 and Phase 3 initiation in Q3 2026.
Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study
Black Diamond Therapeutics NASDAQ: BDTX reported updated Phase 2 data for silevertinib in treatment-naive non-small cell lung cancer patients with EGFR Non-Classical Mutations, saying the investigational therapy produced a preliminary median progression-free survival of 15.2 months in the study cohort.
Implied Volatility Surging for Provident Financial Stock Options
Investors need to pay close attention to PFS stock based on the movements in the options market lately.
Provident Financial Services Remains Compelling As Its Quality Shines Through
Provident Financial Services remains a compelling 'buy' despite recent underperformance versus the S&P 500. PFS demonstrates robust asset quality, attractive valuation, and continued earnings growth, with net profits rising from $64M to $79.4M. Deposit declines are offset by reduced high-cost brokered deposits and loan growth, supporting margin expansion and profitability.
Provident Financial Services, Inc. (PFS) Q1 2026 Earnings Call Transcript
Provident Financial Services, Inc. (PFS) Q1 2026 Earnings Call Transcript
Provident Financial (PFS) Beats Q1 Earnings Estimates
Provident Financial (PFS) came out with quarterly earnings of $0.61 per share, beating the Zacks Consensus Estimate of $0.55 per share. This compares to earnings of $0.5 per share a year ago.
Provident Financial (PFS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Provident Financial (PFS) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Provident Financial (PFS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Provident Financial (PFS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Provident Financial Services: Past Monumental Upside Justifies A Bit More From Here
Provident Financial Services remains a soft ‘buy' as balance sheet growth and asset quality continue to impress despite a 65.8% stock surge since 2024. PFS's deposits and loans have both grown year-over-year, with organic deposit increases and a diversified loan portfolio underpinning stability. Net interest income rose sharply, aided by higher net interest margin and improved credit loss provisions, driving net income to $291.2 million from $115.5 million.
Aftermath Silver kicks off PFS at Berenguela project - ICYMI
Aftermath Silver Ltd (TSX-V:AAG, OTCQX:AAGFF, FRA:FLM1) earlier this week announced the formal launch of a pre-feasibility study (PFS) for its Berenguela project in Peru, marking a significant step forward in the project's development timeline. CEO Ralph Rushton said the company had originally been working toward a preliminary economic assessment but determined that much of the work completed over the past year was already at PFS standard.
Provident Financial Services: Valuation Reflects Strengths
Provident Financial Services is rated "Hold" after a 24% rally, with strengths largely reflected in current valuation. PFS benefits from completed Lakeland Bank integration, robust loan growth, and strong credit quality, but deposit growth and NIM expansion are modest. The bank maintains a solid 12.1% CET1 ratio and a secure 4.2% dividend, prioritizing organic growth over M&A or dividend hikes.
Provident Financial (PFS) Upgraded to Buy: Here's What You Should Know
Provident Financial (PFS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
